BiVictriX Therapeutics Past Earnings Performance
Past criteria checks 0/6
BiVictriX Therapeutics's earnings have been declining at an average annual rate of -39.7%, while the Biotechs industry saw earnings growing at 17.7% annually.
Key information
-39.7%
Earnings growth rate
142.6%
EPS growth rate
Biotechs Industry Growth | 11.5% |
Revenue growth rate | n/a |
Return on equity | -82.2% |
Net Margin | n/a |
Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How BiVictriX Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 23 | 0 | -2 | 1 | 2 |
31 Mar 23 | 0 | -2 | 1 | 2 |
31 Dec 22 | 0 | -2 | 1 | 2 |
30 Sep 22 | 0 | -3 | 1 | 2 |
30 Jun 22 | 0 | -3 | 1 | 2 |
31 Mar 22 | 0 | -3 | 1 | 1 |
31 Dec 21 | 0 | -2 | 1 | 1 |
30 Sep 21 | 0 | -2 | 1 | 0 |
30 Jun 21 | 0 | -1 | 0 | 0 |
31 Mar 21 | 0 | -1 | 0 | 0 |
31 Dec 20 | 0 | 0 | 0 | 0 |
31 Dec 19 | 0 | 0 | 1 | 0 |
Quality Earnings: BVX is currently unprofitable.
Growing Profit Margin: BVX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BVX is unprofitable, and losses have increased over the past 5 years at a rate of 39.7% per year.
Accelerating Growth: Unable to compare BVX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BVX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: BVX has a negative Return on Equity (-82.2%), as it is currently unprofitable.